Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) ...

This is particularly concerning ... People with chronic liver disease (CLD) have a higher likelihood of barriers to health care, according to a study recently published in Gastro Hep Advances.

Discover how sugar modifications, particularly sialic acid, impact mucus formation and transport, contributing to diseases ...

This pathology has a significant impact on patients' lives, including physical, emotional and economic consequences ...

Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In the 7MM ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...